2013 BRIM Founded 2014 Series A (USD 4M) BRM132 In-censed 2015 Series B (USD 26M) PDSP Platform In-licensed 2016 BRM421 U.S. IND Approval 2017 BRM421 U.S. FIH Study BRM132 U.S. IND Approval 2018 Series C (USD 6M) 2019 BRM421 U.S. SIH Study Completed BRM521 Pre-clinical Studies On-going 2020 BRM421 CN Right Licensed to CGP Subsidiary Ascendo Biotech Formed (raised USD 12M)
